These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 8823538)

  • 21. Prevention of foscarnet nephrotoxicity.
    Deray G; Katlama C; Dohin E
    Ann Intern Med; 1990 Aug; 113(4):332. PubMed ID: 2165372
    [No Abstract]   [Full Text] [Related]  

  • 22. Ganciclovir.
    Med Lett Drugs Ther; 1989 Aug; 31(799):79-80. PubMed ID: 2549352
    [No Abstract]   [Full Text] [Related]  

  • 23. Nephrogenic diabetes insipidus associated with foscarnet treatment of cytomegalovirus retinitis.
    Farese RV; Schambelan M; Hollander H; Stringari S; Jacobson MA
    Ann Intern Med; 1990 Jun; 112(12):955-6. PubMed ID: 2160217
    [No Abstract]   [Full Text] [Related]  

  • 24. Antiviral drug-induced kidney and electrolytes disorders.
    Izzedine H; Launay-Vacher V; Isnard-Bagnis C; Deray G
    Minerva Urol Nefrol; 2003 Sep; 55(3):157-72. PubMed ID: 14610435
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Foscarnet. A review of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with cytomegalovirus retinitis.
    Chrisp P; Clissold SP
    Drugs; 1991 Jan; 41(1):104-29. PubMed ID: 1706982
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intravascular foscarnet crystal precipitation causing multiorgan failure.
    Philipponnet C; Michel PA; Daudon M; Brocheriou I; Boffa JJ
    Am J Kidney Dis; 2015 Jan; 65(1):152-5. PubMed ID: 25301103
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Use of ganciclovir to treat serious cytomegalovirus infections in patients with AIDS.
    Laskin OL; Stahl-Bayliss CM; Kalman CM; Rosecan LR
    J Infect Dis; 1987 Feb; 155(2):323-7. PubMed ID: 3027195
    [No Abstract]   [Full Text] [Related]  

  • 28. Foscarnet-induced electrolyte abnormalities in a bone marrow transplant patient receiving parenteral nutrition.
    Matarese LE; Speerhas R; Seidner DL; Steiger E
    JPEN J Parenter Enteral Nutr; 2000; 24(3):170-3. PubMed ID: 10850943
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment and prophylaxis of cytomegalovirus disease.
    Levinson ML; Jacobson PA
    Pharmacotherapy; 1992; 12(4):300-18. PubMed ID: 1325636
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Successful treatment with foscarnet for ganciclovir-resistant cytomegalovirus infection in a kidney transplant recipient: A case report.
    Iwami D; Ogawa Y; Fujita H; Morita K; Sasaki H; Oishi Y; Higuchi H; Hatanaka K; Shinohara N
    Nephrology (Carlton); 2016 Jul; 21 Suppl 1():63-6. PubMed ID: 26970406
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Foscarnet.
    Med Lett Drugs Ther; 1992 Jan; 34(861):3-4. PubMed ID: 1309469
    [No Abstract]   [Full Text] [Related]  

  • 32. Acute renal failure induced by foscarnet: 4 cases.
    Cacoub P; Deray G; Baumelou A; Le Hoang P; Rozenbaum W; Gentilini M; Soubrie C; Rousselie R; Jacobs C
    Clin Nephrol; 1988 Jun; 29(6):315-8. PubMed ID: 2840226
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Prevention of genital erosions during treatments with foscarnet of cytomegalovirus infections in AIDS].
    Lowenstein W; Fadlallah JP; Roudière L; Deneux C; Haas C; Durand H
    Presse Med; 1991 Nov; 20(39):1951. PubMed ID: 1662375
    [No Abstract]   [Full Text] [Related]  

  • 34. Drugs for non-HIV viral infections.
    Treat Guidel Med Lett; 2005 Apr; 3(32):23-32. PubMed ID: 15767977
    [No Abstract]   [Full Text] [Related]  

  • 35. [Adverse effects and safety of antimicrobial agents--nephrotoxicity].
    Sakamoto M
    Nihon Rinsho; 2007 Feb; 65 Suppl 2 Pt. 1():605-8. PubMed ID: 17455689
    [No Abstract]   [Full Text] [Related]  

  • 36. [Treatment of cytomegalovirus infections in immunosuppressed patients].
    Michon C; Girard PM; Ngovan P; Simonpoli AM; Le Hoang P
    Ann Med Interne (Paris); 1988; 139(7):511-5. PubMed ID: 2854380
    [No Abstract]   [Full Text] [Related]  

  • 37. Ganciclovir hepatotoxicity.
    Shea BF; Hoffman S; Sesin GP; Hammer SM
    Pharmacotherapy; 1987; 7(6):223-6. PubMed ID: 2832836
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antiviral drug-induced nephrotoxicity.
    Izzedine H; Launay-Vacher V; Deray G
    Am J Kidney Dis; 2005 May; 45(5):804-17. PubMed ID: 15861345
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment of cytomegaloviral pneumonia with high-dose acyclovir and human leukocyte interferon.
    Wade JC; McGuffin RW; Springmeyer SC; Newton B; Singer JW; Meyers JD
    J Infect Dis; 1983 Sep; 148(3):557-62. PubMed ID: 6311916
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prospects of therapy for infections with human T-lymphotropic virus type III.
    Hirsch MS; Kaplan JC
    Ann Intern Med; 1985 Nov; 103(5):750-5. PubMed ID: 2413793
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.